Combined inhibition of EZH2 and CDK4/6 perturbs endoplasmic reticulum-mitochondrial homeostasis and increases antitumor activity against glioblastoma.
Journal
NPJ precision oncology
ISSN: 2397-768X
Titre abrégé: NPJ Precis Oncol
Pays: England
ID NLM: 101708166
Informations de publication
Date de publication:
25 Jul 2024
25 Jul 2024
Historique:
received:
10
01
2024
accepted:
11
07
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
25
7
2024
Statut:
epublish
Résumé
He, we show that combined use of the EZH2 inhibitor GSK126 and the CDK4/6 inhibitor abemaciclib synergistically enhances antitumoral effects in preclinical GBM models. Dual blockade led to HIF1α upregulation and CalR translocation, accompanied by massive impairment of mitochondrial function. Basal oxygen consumption rate, ATP synthesis, and maximal mitochondrial respiration decreased, confirming disrupted endoplasmic reticulum-mitochondrial homeostasis. This was paralleled by mitochondrial depolarization and upregulation of the UPR sensors PERK, ATF6α, and IRE1α. Notably, dual EZH2/CDK4/6 blockade also reduced 3D-spheroid invasion, partially inhibited tumor growth in ovo, and led to impaired viability of patient-derived organoids. Mechanistically, this was due to transcriptional changes in genes involved in mitotic aberrations/spindle assembly (Rb, PLK1, RRM2, PRC1, CENPF, TPX2), histone modification (HIST1H1B, HIST1H3G), DNA damage/replication stress events (TOP2A, ATF4), immuno-oncology (DEPDC1), EMT-counterregulation (PCDH1) and a shift in the stemness profile towards a more differentiated state. We propose a dual EZH2/CDK4/6 blockade for further investigation.
Identifiants
pubmed: 39054369
doi: 10.1038/s41698-024-00653-3
pii: 10.1038/s41698-024-00653-3
doi:
Types de publication
Journal Article
Langues
eng
Pagination
156Informations de copyright
© 2024. The Author(s).
Références
Banerjee, K. et al. Current approaches for glioma gene therapy and virotherapy. Front. Mol. Neurosci. 14, 621831 (2021).
pubmed: 33790740
pmcid: 8006286
doi: 10.3389/fnmol.2021.621831
Silantyev et al. Current and future trends on diagnosis and prognosis of glioblastoma: from molecular biology to proteomics. Cells 8, 863 (2019).
pubmed: 31405017
pmcid: 6721640
doi: 10.3390/cells8080863
Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro. Oncol. 23, 1231–1251 (2021).
pubmed: 34185076
pmcid: 8328013
doi: 10.1093/neuonc/noab106
Liu, H. et al. EZH2 phosphorylation promotes self-renewal of glioma stem-like cells through NF-κB methylation. Front. Oncol. 9, 641 (2019).
pubmed: 31380279
pmcid: 6652807
doi: 10.3389/fonc.2019.00641
Zhao, G. et al. Targeting EZH2 regulates the biological characteristics of glioma stem cells via the Notch1 pathway. Exp. Brain Res. 241, 2409–2418 (2023).
pubmed: 37644332
doi: 10.1007/s00221-023-06693-8
Yu, T. et al. EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma. Oncogene 42, 461–470 (2023).
pubmed: 36517590
doi: 10.1038/s41388-022-02570-w
Yang, R. et al. E2F7-EZH2 axis regulates PTEN/AKT/mTOR signalling and glioblastoma progression. Br. J. Cancer 123, 1445–1455 (2020).
pubmed: 32814835
pmcid: 7591888
doi: 10.1038/s41416-020-01032-y
Wong, Y. P. et al. High EZH2 protein expression is a poor prognostic predictor in IDH1 R132H-negative gliomas. Diagnostics (Basel) 12, 2383 (2022).
pubmed: 36292072
doi: 10.3390/diagnostics12102383
Del Moral-Morales, A. et al. EZH2 mediates proliferation, migration, and invasion promoted by estradiol in human glioblastoma cells. Front. Endocrinol. 13, 703733 (2022).
doi: 10.3389/fendo.2022.703733
Ratnam, N. M. et al. Reversing epigenetic gene silencing to overcome immune evasion in CNS malignancies. Front. Oncol. 11, 719091 (2021).
pubmed: 34336705
pmcid: 8320893
doi: 10.3389/fonc.2021.719091
Scuderi, S. A. GSK343, an inhibitor of enhancer of zeste homolog 2, reduces glioblastoma progression through inflammatory process modulation: focus on canonical and non-canonical NF-κB/IκBα pathways. Int. J. Mol. Sci. 23, 13915 (2022).
pubmed: 36430394
pmcid: 9694970
doi: 10.3390/ijms232213915
Sun, W. et al. Targeting EZH2 depletes LMP1-induced activated regulatory T cells enhancing antitumor immunity in nasopharyngeal carcinoma. J. Cancer Res. Ther. 16, 309–319 (2020).
pubmed: 32474518
doi: 10.4103/jcrt.JCRT_986_19
Qi, L. et al. Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies. Lab. Investig. 102, 185–193 (2022).
pubmed: 34802040
doi: 10.1038/s41374-021-00700-8
Duan, R., Du, W. & Guo, W. EZH2: a novel target for cancer treatment. J. Hematol. Oncol. 13, 1–12 (2020).
doi: 10.1186/s13045-020-00937-8
Zeng, D. et al. Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells. Oncotarget 8, 3396–3411 (2016).
pmcid: 5356890
doi: 10.18632/oncotarget.13773
Zhai, X. EZH2 regulates the malignancy of human glioblastoma cells via modulation of twist mRNA stability. Eur. J. Pharmacol. 904, 174177 (2021).
pubmed: 34015321
doi: 10.1016/j.ejphar.2021.174177
Li, C. et al. Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors. Clin. Epigenet. 13, 1–12 (2021).
doi: 10.1186/s13148-021-01045-1
Jardim, D. L. et al. Cyclin pathway genomic alterations across 190,247 solid tumors: leveraging large-scale data to inform therapeutic directions. Oncologist 26, e78–e89 (2021).
pubmed: 32885893
doi: 10.1634/theoncologist.2020-0509
Vij, M. et al. P16 immunohistochemistry is a sensitive and specific surrogate marker for CDKN2A homozygous deletion in gliomas. Acta Neuropathol. Commun. 11, 73 (2023).
pubmed: 37138345
pmcid: 10155323
doi: 10.1186/s40478-023-01573-2
Funakoshi, Y. et al. Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma. Cancer Med. 10, 3177–3187 (2021).
pubmed: 33838014
pmcid: 8124111
doi: 10.1002/cam4.3860
Riess, C. et al. Implementation of a combined CDK inhibition and arginine-deprivation approach to target arginine-auxotrophic glioblastoma multiforme cells. Cell Death Dis. 13, 555 (2022).
pubmed: 35717443
pmcid: 9206658
doi: 10.1038/s41419-022-05006-1
Riess, C. et al. Cyclin-dependent kinase inhibitors exert distinct effects on patient-derived 2D and 3D glioblastoma cell culture models. Cell Death Discov. 7, 54 (2021).
pubmed: 33723248
pmcid: 7961149
doi: 10.1038/s41420-021-00423-1
Corona, S. P. & Generali, D. Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer. Drug Des. Devel. Ther. 12, 321–330 (2018).
pubmed: 29497278
pmcid: 5818877
doi: 10.2147/DDDT.S137783
Goetz, M. P. et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J. Clin. Oncol. 35, 3638–3646 (2017).
pubmed: 28968163
doi: 10.1200/JCO.2017.75.6155
Wu, T. et al. Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo. Biochem. Pharmacol. 124, 29–42 (2017).
pubmed: 27816545
doi: 10.1016/j.bcp.2016.10.015
Bronner, S. M. et al. Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma. Bioorg. Med. Chem. Lett. 29, 2294–2301 (2019).
pubmed: 31307887
doi: 10.1016/j.bmcl.2019.06.021
Kellie Turner, P. et al. Abemaciclib does not have a clinically meaningful effect on pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 substrates in patients with cancer. Drug Metab. Dispos. 48, 796–803 (2020).
pubmed: 32581049
doi: 10.1124/dmd.119.090092
Kaniskan, H. Ü., Martini, M. L. & Jin, J. Inhibitors of protein methyltransferases and demethylases. Chem. Rev. 118, 989–1068 (2018).
pubmed: 28338320
doi: 10.1021/acs.chemrev.6b00801
Liu, W. J. et al. p62 links the autophagy pathway and the ubiqutin-proteasome system upon ubiquitinated protein degradation. Cell. Mol. Biol. Lett. 21, 1–14 (2016).
doi: 10.1186/s11658-016-0031-z
Smith, J., Field, M. & Sugaya, K. Suppression of NANOG expression reduces drug resistance of cancer stem cells in glioblastoma. Genes 14, 1276 (2023).
pubmed: 37372456
pmcid: 10297980
doi: 10.3390/genes14061276
Nakod, P. S., Kondapaneni, R. V., Edney, B., Kim, Y. & Rao, S. S. The impact of temozolomide and lonafarnib on the stemness marker expression of glioblastoma cells in multicellular spheroids. Biotechnol. Prog. 38, e3284 (2022).
pubmed: 35768943
doi: 10.1002/btpr.3284
Ishii, H. et al. Isolation and characterization of cancer stem cells derived from human glioblastoma. Am. J. Cancer Res. 11, 441 (2021).
pubmed: 33575080
pmcid: 7868757
Figarella-Branger, D., Colin, C., Baeza-Kallee, N. & Tchoghandjian, A. A2B5 expression in central nervous system and gliomas. Int. J. Mol. Sci. 23, 4670 (2022). 2022, Vol. 23, Page 4670.
pubmed: 35563061
pmcid: 9103745
doi: 10.3390/ijms23094670
Sun, T. et al. Aggressive invasion is observed in CD133-/A2B5+ glioma-initiating cells. Oncol. Lett. 10, 3399–3406 (2015).
pubmed: 26788141
pmcid: 4665828
doi: 10.3892/ol.2015.3823
Noronha, C. et al. Cadherin expression and EMT: a focus on gliomas. Biomedicines 9, 1328 (2021).
pubmed: 34680444
pmcid: 8533397
doi: 10.3390/biomedicines9101328
Pinto, J. P. et al. StemChecker: a web-based tool to discover and explore stemness signatures in gene sets. Nucleic Acids Res. 43, W72 (2015).
pubmed: 26007653
pmcid: 4489266
doi: 10.1093/nar/gkv529
Zhang, L. et al. EZH2-, CHD4-, and IDH-linked epigenetic perturbation and its association with survival in glioma patients. J. Mol. Cell Biol. 9, 477–488 (2017).
pubmed: 29272522
doi: 10.1093/jmcb/mjx056
Stazi, G. et al. Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype. Clin. Epigenet. 11, 173 (2019).
doi: 10.1186/s13148-019-0763-5
Straining, R. & Eighmy, W. Tazemetostat: EZH2 inhibitor. J. Adv. Pract. Oncol. 13, 158 (2022).
pubmed: 35369397
pmcid: 8955562
doi: 10.6004/jadpro.2022.13.2.7
Liu, H. et al. Therapeutic strategies of glioblastoma (GBM): the current advances in the molecular targets and bioactive small molecule compounds. Acta Pharm. Sin. B 12, 1781–1804 (2022).
pubmed: 35847506
doi: 10.1016/j.apsb.2021.12.019
Ma, G. F. et al. HER2 mRNA status contributes to the discrepancy between gene amplification and protein overexpression in gastric cancer. Dig. Dis. Sci. 59, 328–335 (2014).
pubmed: 24185685
doi: 10.1007/s10620-013-2925-1
Cousins, E. M. et al. Competitive kinase enrichment proteomics reveals that abemaciclib inhibits GSK3β and activates WNT signaling. Mol. Cancer Res. 16, 333–344 (2018).
pubmed: 29133594
doi: 10.1158/1541-7786.MCR-17-0468
& Billard-Sandu, C. CDK4/6 inhibitors in P16/HPV16-negative squamous cell carcinoma of the head and neck. Eur. Arch. Otorhinolaryngol. 277, 1273–1280 (2020).
pubmed: 32162057
doi: 10.1007/s00405-020-05891-2
Su, D. et al. Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinoma. Nat. Commun. 10, 5076 (2019).
pubmed: 31700061
pmcid: 6838071
doi: 10.1038/s41467-019-12846-7
Schoenwaelder, N. et al. Preclinical head and neck squamous cell carcinoma models for combined targeted therapy approaches. Cancers 14, 2484 (2022).
pubmed: 35626088
pmcid: 9139292
doi: 10.3390/cancers14102484
Dan, S. et al. Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations. Cancer Res. 70, 4982–4994 (2010).
pubmed: 20530683
doi: 10.1158/0008-5472.CAN-09-4172
Samarzija, I., Tomljanovic, M., Novak Kujundzic, R. & Troselj, K. G. EZH2 inhibition and cisplatin as a combination anticancer therapy: an overview of preclinical studies. Cancers (Basel) 14, 4761 (2022).
pubmed: 36230683
doi: 10.3390/cancers14194761
Daures, M. et al. A new metabolic gene signature in prostate cancer regulated by JMJD3 and EZH2. Oncotarget 9, 23413–23425 (2018).
pubmed: 29805743
pmcid: 5955128
doi: 10.18632/oncotarget.25182
Liu, L. et al. Ezh2 promotes mammary tumor initiation through epigenetic regulation of the Wnt and mTORC1 signaling pathways. Proc. Natl. Acad. Sci. USA 120, e2303010120 (2023).
pubmed: 37549258
pmcid: 10438390
doi: 10.1073/pnas.2303010120
Shi, J. et al. HOTAIR-EZH2 inhibitor AC1Q3QWB upregulates CWF19L1 and enhances cell cycle inhibition of CDK4/6 inhibitor palbociclib in glioma. Clin. Transl. Med. 10, 182–198 (2020).
pubmed: 32508030
pmcid: 7240863
doi: 10.1002/ctm2.21
Kanzawa, T. et al. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 11, 448–457 (2004). 2004 114.
pubmed: 14713959
doi: 10.1038/sj.cdd.4401359
Yu, T. et al. The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells. Oncotarget 8, 98348–98359 (2017).
pubmed: 29228694
pmcid: 5716734
doi: 10.18632/oncotarget.21311
Wang, Z., Zhang, S., Siu, T. L. & Huang, S. Glioblastoma multiforme formation and EMT: role of FoxM1 transcription factor. Curr. Pharm. Des. 21, 1268 (2015).
pubmed: 25506897
pmcid: 4380124
doi: 10.2174/1381612821666141211115949
Dong, C. et al. Identification of the proliferative effect of Smad2 and 3 in the TGF β2/Smad signaling pathway using RNA interference in a glioma cell line. Mol. Med. Rep. 12, 1824 (2015).
pubmed: 25891822
pmcid: 4464434
doi: 10.3892/mmr.2015.3614
Paredes, F. et al. Metabolic regulation of the proteasome under hypoxia by Poldip2 controls fibrotic signaling in vascular smooth muscle cells. Free Radic. Biol. Med. 195, 283–297 (2023).
pubmed: 36596387
doi: 10.1016/j.freeradbiomed.2022.12.098
Kaundal, B., Karmakar, S. & Roy Choudhury, S. Mitochondria-targeting nano therapy altering IDH2-mediated EZH2/EZH1 interaction as precise epigenetic regulation in glioblastoma. Biomater. Sci. 10, 5301–5317 (2022).
pubmed: 35917200
doi: 10.1039/D1BM02006D
D’Angiolella, V. et al. Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell 149, 1023–1034 (2012).
pubmed: 22632967
pmcid: 3616325
doi: 10.1016/j.cell.2012.03.043
Perrault, E. N. et al. Ribonucleotide reductase regulatory subunit M2 drives glioblastoma TMZ resistance through modulation of dNTP production. Sci. Adv. 9, eade7236 (2023).
pubmed: 37196077
pmcid: 10191446
doi: 10.1126/sciadv.ade7236
Corrales-Guerrero, S. et al. Inhibition of RRM2 radiosensitizes glioblastoma and uncovers synthetic lethality in combination with targeting CHK1. Cancer Lett. 570, 216308 (2023).
pubmed: 37482342
doi: 10.1016/j.canlet.2023.216308
Liu, Y. et al. DNA topoisomerase II alpha promotes the metastatic characteristics of glioma cells by transcriptionally activating β-catenin. Bioengineered 13, 2207 (2022).
pubmed: 35012441
pmcid: 8974225
doi: 10.1080/21655979.2021.2023985
Kong, W. Z., Liu, Y. S., Gao, X. D. & Fujita, M. Comprehensive in silico analysis of glycosylphosphatidylinositol- anchored protein (GPI-AP) related genes expression profiles in human normal and cancer tissues. Yi Chuan Hered. 45, 669–683 (2023).
Eyme, K. M. et al. Targeting de novo lipid synthesis induces lipotoxicity and impairs DNA damage repair in glioblastoma mouse models. Sci. Transl. Med. 15, eabq6288 (2023).
pubmed: 36652537
pmcid: 9942236
doi: 10.1126/scitranslmed.abq6288
Zhang, X. et al. PLK4 initiates crosstalk between cell cycle, cell proliferation and macrophages infiltration in gliomas. Front. Oncol. 12, 1055371 (2022).
pubmed: 36620611
pmcid: 9815703
doi: 10.3389/fonc.2022.1055371
Pei, J. P. et al. AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage. Acta Pharmacol. Sin. 44, 1290–1303 (2023).
pubmed: 36650292
pmcid: 10203350
doi: 10.1038/s41401-022-01047-6
Walentynowicz, K. A. et al. Single-cell heterogeneity of EGFR and CDK4 co-amplification is linked to immune infiltration in glioblastoma. Cell Rep. 42, 112235 (2023).
pubmed: 36920905
pmcid: 10114292
doi: 10.1016/j.celrep.2023.112235
Chen, X., Hu, Y., Wang, S. & Sun, X. The regulator of calcineurin 1 (RCAN1) inhibits nuclear factor kappaB signaling pathway and suppresses human malignant glioma cells growth. Oncotarget 8, 12003–12012 (2017).
pubmed: 28061453
pmcid: 5355321
doi: 10.18632/oncotarget.14479
Liu, B. et al. RND3 promotes Snail 1 protein degradation and inhibits glioblastoma cell migration and invasion. Oncotarget 7, 82411–82423 (2016).
pubmed: 27705942
pmcid: 5347701
doi: 10.18632/oncotarget.12396
Salewski, I. et al. CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors. Oncoimmunology 11, 2094583 (2022).
pubmed: 35845723
pmcid: 9278458
doi: 10.1080/2162402X.2022.2094583
Strüder, D. et al. Establishment and characterization of patient-derived head and neck cancer models from surgical specimens and endoscopic biopsies. J. Exp. Clin. Cancer Res. 40, 246 (2021).
pubmed: 34362423
pmcid: 8344210
doi: 10.1186/s13046-021-02047-w
Koczan, D., Fitzner, B., Zettl, U. K. & Hecker, M. Microarray data of transcriptome shifts in blood cell subsets during S1P receptor modulator therapy. Sci. Data 5, 180145 (2018).
pubmed: 30040082
pmcid: 6057441
doi: 10.1038/sdata.2018.145
Hong, G., Zhang, W., Li, H., Shen, X. & Guo, Z. Separate enrichment analysis of pathways for up- and downregulated genes. J. R. Soc. Interface 11, 20130950 (2014).
pubmed: 24352673
pmcid: 3899863
doi: 10.1098/rsif.2013.0950
Chicco, D. & Agapito, G. Nine quick tips for pathway enrichment analysis. PLoS Comput. Biol. 18, e1010348 (2022).
pubmed: 35951505
pmcid: 9371296
doi: 10.1371/journal.pcbi.1010348
Szklarczyk, D. et al. The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 49, D605 (2021).
pubmed: 33237311
doi: 10.1093/nar/gkaa1074
Raudvere, U. et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 47, W191–W198 (2019).
pubmed: 31066453
pmcid: 6602461
doi: 10.1093/nar/gkz369
Maletzki, C. et al. Establishing safe high hydrostatic pressure devitalization thresholds for autologous head and neck cancer vaccination and reconstruction. Cell Death Discov. 9, 390 (2023).
pubmed: 37872173
pmcid: 10593744
doi: 10.1038/s41420-023-01671-z
Linke, C. et al. The addition of arginine deiminase potentiates mithramycin a-induced cell death in patient-derived glioblastoma cells via ATF4 and cytochrome C. Cancer Cell Int. 23, 38 (2023).
pubmed: 36843002
pmcid: 9969664
doi: 10.1186/s12935-023-02873-2
Jacob, F. et al. A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity. Cell 180, 188–204.e22 (2020).
pubmed: 31883794
doi: 10.1016/j.cell.2019.11.036